Prechemotherapy serum levels of CD105, transforming growth factor β2, and vascular endothelial growth factor are associated with prognosis in patients with advanced epithelial ovarian cancer treated with cytoreductive surgery and platinum-based chemotherapy

International Journal of Gynecological Cancer

Volumn 20, Issue 2, 2010, Pages 248-254

  Bozas, George ^a   Terpos, Evangelos ^b   Gika, Dimitra ^a   Karadimou, Alexandra ^a   Dimopoulos, Meletios A ^a   Bamias, Aristotelis ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b General Air Force Hospital   (Greece)

Author keywords

CD105; Endoglin; Ovarian cancer; TGF; VEGF

Indexed keywords

ANGIOPOIETIN 2; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ENDOGLIN; PACLITAXEL; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; TGFB2 PROTEIN, HUMAN; VASCULOTROPIN A;

ADULT; ADVANCED CANCER; AGED; ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; BLOOD; MIDDLE AGED; NEOPLASM; OVARY TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTORS, CELL SURFACE; RETROSPECTIVE STUDIES; TRANSFORMING GROWTH FACTOR BETA2; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 77951920654     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181cc25c3     Document Type: Article

References (31)

1. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19:3-10.
2. Gougos A, Letarte M. Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol. 1988;141:1925-1933.
3. Kikuchi R, Tsuda H, Kozaki K, et al. Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer. Cancer Res. 2008;68:5067-5075.
4. Hata K, Nakayama K, Fujiwaki R, et al. Expression of the andiopoietin-1, angiopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer. Gynecol Oncol. 2004;93:215-222.
5. Miller DW, Graulich W, Karges B, et al. Elevated expression of endoglin, a component of the TGF-betaYreceptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer. 1999;81:568-1572.
6. Burrows FJ, Derbyshire EJ, Tazzari PL, et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res. 1995;1:1623-1634.
7. Fonsatti E, Maio M. Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Transl Med. 2004;2:18-27.
8. Li C, Hampson IN, Hampson L, et al. CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. FASEB J. 2000;14:55-64.
9. Li C, Issa R, Kumar P, et al. CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci. 2003;116:2677-2685.
10. Duff SE, Li C, Garland JM, et al. CD105 is important for angiogenesis: evidence and potential applications. FASEB J. 2003;17:984-992.
11. Takahashi N, Kawanishi-Tabata R, Haba A, et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res. 2001;7:524-532.
12. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342:1350-1358.
13. Rodriguez GC, Haisley C, Hurteau J, et al. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. Gynecol Oncol. 2001;80:245-253.
14. Hollingsworth HC, Kohn EC, Steinberg SM, et al. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol. 1995;147:33-41.
15. Taskiran C, Erdem O, Onan A, et al. The prognostic value of endoglin (CD105) expression in ovarian carcinoma. Int J Gynecol Cancer. 2006;16:1789-1793.
16. Aravantinos G, Fountzilas G, Bamias A, et al. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first line chemotherapy of advanced ovarian cancer. Eur J Cancer. 2008;44:2169-2177.
17. Hurteau JA, Rodriguez GC, Whitaker RS, et al. Transforming growth factor-A inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer. 1994;74:93-99.
18. Havrilesky LJ, Hurteau JA, Whitaker RS, et al. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor A1. Cancer Res. 1995;55:944-948.
19. Garcea G, Neal CP, Pattenden CJ, et al. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer. 2005;41:2213-2236.
20. Bartlett JM, Langdon SP, Scott WN, et al. Transforming growth factor-A isoform expression in human ovarian tumors. Eur J Cancer. 1997;33:2397-2403.
21. Sonmezer M, Gungor M, Ensari A, et al. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor beta and vascular endothelial growth factor. Int J Gynecol Cancer. 2004;14:82-88.
22. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. New Engl J Med. 2001;344:1196-1206.
23. Kopp A, Jonat W, Schmahl M, et al. Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res. 1995;55:4512-4515.
24. Furstenberger G, von Moos R, Lucas R, et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer. 2006;94:524-531.
25. Kumar S, Ghellal A, Li C, et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res. 1999;59:856-861.
26. Dales JP, Garcia S, Carpentier S, et al. Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n = 905). Br J Cancer. 2004;90:1216-1221.
27. Wikstrom P, Lissbrant IF, Stattin P, et al. Endoglin is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate. 2002;51:268-275.
28. Salvesen HB, Gulluoglu MG, Stefansson I, et al. Significance of CD105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. APMIS. 2003;111:1011-1018.
29. Hata K, Osaki M, Dhar DK, et al. Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line. Cancer Chemother Pharmacol. 2004;53:68-74.
30. Bamias A, Kyriakou F, Chorti M, et al. Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/A-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: a Hellenic Cooperative Oncology Group (HECOG) Study. Anticaner Res. 2008;28:2479-2486.
31. Bamias A, Koutsoukou V, Terpos E, et al. Correlation of NKT-like CD3+CD56+ cells and CD4+CD25+ (hi) regulatory T cells with VEGF and TNF> in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol Oncol. 2008;108:421-427.